Browse the search results

MKLP2 is a divergent molecular motor that has structurally evolved to bind its microtubule track and use the energy of ATP in distinct ways, tuned according to its function in cell division.

Inhibition of ITGA2-mediated cancer cell-collagen interaction or targeting focal adhesion kinase activity may present an opportunity for therapeutic intervention of metastatic spread in ovarian cancer.

Stereotactic body radiotherapy combined with immunotherapy and chemotherapy in neoadjuvant setting exhibited a promising anti-tumor activity and an acceptable safety profile in triple-negative breast cancer patients.

Deletion of delta-tubulin or epsilon-tubulin in human cells results in loss of centriolar triplet microtubules and defects in centriole structure and inheritance.

Treatment with precision nanomedicine in combination with an anti-angiogenic peptide enhance anti-tumor efficacy while minimizing toxicities in a pre-clinical glioblastoma model, making this approach a promising and important therapeutic alternative for patients.

Inhibiting the RiBi pathway impedes both EMT and MET processes, enhancing chemotherapy efficacy and presenting a novel avenue to tackle advanced breast cancer treatment resistance.

Stromules induced during plant innate immunity dynamically interact and use the cytoskeleton to form and to direct the movement of chloroplasts.

Cancer-directed treatment using Tumor-Treating Fields spatially modulates the tumor microenvironment at the cellular and molecular levels, decreasing nanotube-based cellular networks of communication while creating a microenvironment more susceptible to immunotherapeutic strategies.

Cancer cells can grow in vitro and in vivo in the absence of maternal embryonic leucine zipper kinase (MELK).